

IM BOARD REVIEW

MARSHALL EDWARD McCABE IV, DO
Indiana University School of Medicine, Indianapolis**AREEBA Y. KARA, MD, MS, FACP**
Inpatient Medicine, IU Health University Hospital;
Assistant Clinical Professor of Medicine, Indiana
University School of Medicine, IndianapolisA SELF-TEST
ON A
CLINICAL
CASE
.....

A 56-year-old with diarrhea and weakness

A 56-YEAR-OLD MAN presents to the emergency department with nausea, weakness, and exertional dyspnea, which have been going on for 1 week. He is sent by his primary care physician after being noted to be hypotensive with a weak, thready pulse.

He has had diarrhea with intermittent abdominal pain over the past year, with 10 stools daily, including 3 or 4 at night. The stools are described as large, nonbloody, sticky, greasy, and occasionally watery. Stools are fewer when he curtails his food intake. The diarrhea is associated with occasional diffuse abdominal pain he describes as a burning sensation. He has no incontinence or tenesmus. He reports that he has unintentionally lost 137 lb (62 kg) over the past year. He has not taken over-the-counter antidiarrheal agents.

■ CHRONIC DIARRHEA

1 Chronic diarrhea is defined as lasting for at least how long?

- 1 week
- 2 weeks
- 3 weeks
- 4 weeks

Chronic diarrhea is defined as looser stools for more than 4 weeks,¹ a period that allows most cases of acute, self-limited, infectious diarrhea to resolve.

Because individuals perceive diarrhea differently, reported prevalence rates of chronic diarrhea vary.² Based on the definition of having excessive stool frequency, the prevalence in the United States is about 5%.¹

doi:10.3949/ccjm.82a.14124

In developing countries, the most common cause of chronic diarrhea is infection. In developed nations, irritable bowel syndrome, inflammatory bowel disease, malabsorption syndrome, and chronic infection predominate.¹

Once chronicity is established, diarrhea should be characterized as inflammatory, fatty, or watery (Table 1).³

■ CASE CONTINUED: HISTORY OF HYPERTENSION, DIABETES

Our patient reports that he has never traveled outside the United States. He has a history of hypertension and type 2 diabetes mellitus that is controlled on oral agents. He has had surgery for a radial fracture and for reconstruction of his knees. He uses no tobacco, alcohol, or illicit drugs and works as a train engineer. He has no pets. He knows of no family history of inflammatory bowel disease or chronic diarrhea.

Comment. Patients with diabetes are at increased risk of gastrointestinal problems, with severity increasing with poorer control.⁴ Although our patient's diabetes puts him at risk of diabetic autonomic neuropathy, his blood glucose control has been consistently good since his diagnosis, and his last measured hemoglobin A_{1c} was 7.3% (reference range 4%–7%). His description of greasy stools in conjunction with his marked weight loss puts fatty diarrhea higher on the differential diagnosis.

■ DRUG-INDUCED DIARRHEA

His medications include glimepiride 1 mg twice daily, lisinopril 10 mg daily, metformin 500 mg twice daily, omeprazole 40 mg daily, and naproxen 220 mg daily. He has been tak-

He has unintentionally lost 137 lb over the past year; what is the cause?

TABLE 1

Characteristics of diarrheal types

Diarrheal type	Pathophysiology	Clinical features	Common causes	Testing
Inflammatory	Inflamed mucosa	Small-volume, bloody stools Associated tenesmus Abdominal pain and possibly fever	Infection Inflammatory bowel disease Ischemia Radiation	Stool leukocytes Direct visualization and biopsy of mucosa with flexible sigmoidoscopy or colonoscopy
Fatty	Malabsorption, maldigestion	Weight loss Bulky, greasy, sticky stools	Celiac disease Pancreatic exocrine insufficiency Small-bowel intestinal bacterial overgrowth	Sudan stain for fat in stool Small-bowel biopsy Pancreatic imaging Hydrogen breath testing
Watery	Osmotic	Watery stools that improve with fasting	Lactose intolerance Laxative ingestion	Fecal osmotic gap > 50 mmol/L Stool pH < 6 with carbohydrate malabsorption Colonoscopy
	Secretory	Watery stools, no change with fasting	Infection Inflammatory bowel disease Bile acid malabsorption Post-vagotomy Diabetic neuropathy Endocrine tumors	Fecal osmotic gap < 50 mmol/L Colonoscopy Endocrine testing if supporting signs and symptoms are present

ing metformin for at least 2 years. He is allergic to pentobarbital.

2 Which of his medications is least likely to be associated with his diarrhea?

- Lisinopril
- Metformin
- Glimepiride
- Naproxen

More than 700 drugs are known to cause diarrhea, often through the interplay of simultaneous mechanisms.⁵ The diagnosis of drug-induced diarrhea requires taking a careful medication history and establishing a temporal relationship between the drug and the diarrheal symptoms. Treatment consists of withdrawing the offending agent.

Nonsteroidal anti-inflammatory drugs (eg, naproxen) are associated with collagenous colitis that occurs mostly after long-term use (> 6 months). Metformin-induced diarrhea is related to fat malabsorption.⁵ Olmesartan, an angiotensin II receptor antagonist, has been associated with severe sprue-like enteropathy.⁶ On the other hand, the incidence of diarrhea with lisinopril is similar to that with placebo.⁷

**■ CASE CONTINUED:
EXAMINATION AND LABORATORY VALUES**

The patient's primary care physician had recently referred him to a gastroenterologist, and 4 days before presenting to the emergency department he had undergone abdominal and

pelvic computed tomography (CT) with iodinated contrast, which had showed hepatic steatosis and pancreatic atrophy.

On examination now, the patient's temperature is 97.5°F (36.4°C), heart rate 90 beats per minute, respirations 18 breaths per minute, oxygen saturation 99% on room air, and blood pressure 85/55 mm Hg. His body mass index is 32.5 kg/m². His oral mucosa is dry. The rest of the examination is normal. No rash or ulcers are noted.

His laboratory values (Table 2) are notable for sodium 130 mmol/L, potassium 2.2 mmol/L, bicarbonate 9 mmol/L, blood urea nitrogen 32 mg/dL, creatinine 4.18 mg/dL, and international normalized ratio 5.4. Arterial blood gases drawn on admission reveal pH 7.32 and pCO₂ 19 mm Hg.

ACID-BASE DISTURBANCES

3 The patient's acidosis is most likely related to which of the following?

- Sepsis
- Diarrhea
- Metformin
- Acute kidney injury

It is most likely related to diarrhea. The patient has a non-anion-gap metabolic acidosis. (The anion gap can be calculated by subtracting the sum of the serum bicarbonate and chloride values from the sodium—here, 130 – [112 + 9] = 9—and most textbooks list the reference range as 10–12 mmol/L.) Non-anion-gap metabolic acidosis results from excessive loss of bicarbonate or impaired ability of the kidney to excrete acid. Bicarbonate losses can occur in diarrhea or in ureteral diversion to the colon. Impairment in urinary acidification can occur in renal tubular acidosis.

To determine the cause of non-anion-gap acidosis, calculating the urine anion gap can be useful (Table 3), as it reflects the ability of the kidneys to excrete acid and is an indirect measure of ammonium excretion. Our patient's urine anion gap is –45 mmol/L ([62 + 8] – 115), which supports diarrhea as the cause of his non-anion-gap acidosis. Sepsis, metformin use, or acute kidney injury would result in an anion-gap acidosis.

To manage acid-base disturbances, it is

TABLE 2

Our patient's laboratory results

Test	4 days before admission	On admission	Reference range
Sodium (mmol/L)		130	135–146
Potassium (mmol/L)		2.2	3.5–5.0
Chloride (mmol/L)		112	98–110
Bicarbonate (mmol/L)		9	23–32
Blood urea nitrogen (mg/dL)	16	32	10–25
Creatinine (mg/dL)	1.3	4.18	0.70–1.40
Glucose (mg/dL)		209	—
Calcium (mg/dL)		8.7	8.5–10.5
Magnesium (mg/dL)		1.5	1.7–2.6
Phosphorus (mg/dL)		2.5	2.5–4.5
Alanine aminotransferase (U/L)		68	5–50
Aspartate aminotransferase (U/L)		65	7–40
Total bilirubin (mg/dL)		0.8	0–1.5
Albumin (g/dL)		3.4	3.5–5.5
International normalized ratio		5.4	0.8–1.2
White blood cell count (× 10 ⁹ /L)		13.6	3.7–11.0
Hemoglobin (g/dL)		16.4	13.0–17.0
Platelet count (× 10 ⁹ /L)		254	150–400
pH		7.32	7.32–7.42
pCO ₂ (mm Hg)		19	42–55
Urine studies			
Sodium (mmol/L)		62	14–216
Potassium (mmol/L)		8	0–160
Chloride (mmol/L)		115	16–250
Creatinine (mg/dL)		59	20–300

important to first determine whether there is a single primary disturbance with compensation or a mixed disorder. In the case of metabolic acidosis, for every 1-mmol/L decrease in bicarbonate, there should be a corresponding 1.3-mm Hg decrease in pCO₂. Our patient's laboratory data show that he had a pure non-anion-gap metabolic acidosis.⁸ His sensation of dyspnea was likely related to respiratory compensation as evidenced by an appropriately low pCO₂.

TABLE 3

Urine anion gap

The urine anion gap is calculated from urine laboratory values as follows:

$$\text{Anion gap} = (\text{sodium} + \text{potassium}) - \text{chloride}$$

Results

Negative anion gap: gastrointestinal losses

Positive anion gap: renal acid excretion

**■ CASE CONTINUED:
HIS LABORATORY VALUES IMPROVE**

The patient is admitted to the hospital for fluid resuscitation with normal saline and potassium and magnesium replacement.

Renal ultrasonography reveals normal-appearing kidneys without obstruction. The calculated fractional excretion of sodium is 3.4%. Urine microscopy reveals two to five hyaline casts per low-power field. His urine output remains adequate, and 3 days after hospitalization, his renal function starts to improve, as reflected in falling serum creatinine and blood urea nitrogen levels: his creatinine level has declined to 1.91 mg/dL and his blood urea nitrogen level has declined to 24 mg/dL. His acute kidney injury is attributed to intravenous contrast given for computed tomography, as well as to volume depletion and hypotension.

Stool studies for ova, parasites, and *Clostridium difficile* are negative. Fecal calprotectin and lactoferrin are useful noninvasive markers of intestinal inflammation⁹ but were not checked in this case.

Loperamide, taken as needed, is started for his diarrhea, along with empiric pancreatic enzyme replacement. After 3 days of treatment with oral vitamin K 10 mg, his international normalized ratio comes down to 1.4, from his admission value of 5.4. Given the clinical concern for fat malabsorption, vitamin D levels are also checked: his 25-hydroxyvitamin D level is less than 10 ng/mL (lower limit of normal 20). His fecal neutral fats are reported as normal, but split fats are increased.

■ STOOL FAT STUDIES

4 What does increased fecal split fats but normal fecal neutral fats imply?

- Pancreatic insufficiency
- Intestinal malabsorption
- Does not differentiate between the two

The finding does not differentiate between pancreatic insufficiency and intestinal malabsorption. The two-step Sudan stain has been used to differentiate maldigestion (eg, caused by pancreatic insufficiency) from malabsorption. Although patients with impaired digestion were once thought to excrete excessive amounts of intact triglyceride whereas those with malabsorption excrete more of the lipolytic or “split” product, the Sudan stain does not differentiate between the two.¹⁰ Stool fecal-elastase 1 testing correlates well with pancreatic exocrine function but was not performed in our patient.¹¹

**■ CASE CONTINUED:
CELIAC DISEASE IS DIAGNOSED**

Given the description of his stools, unintentional weight loss, and improvement of stool frequency with fasting, serologic testing for celiac disease is performed (Table 4). The patient undergoes esophagogastroduodenoscopy, which shows mild duodenitis. Small-bowel biopsy reveals blunted villous architecture and increased mixed inflammatory cells of the epithelium and lamina propria, suggestive of celiac disease.

The patient is diagnosed with celiac disease and is counseled to follow a gluten-free diet. He is discharged home and scheduled to follow up with a gastroenterologist and nephrologist. His liver function test abnormalities are attributed to a combination of nonalcoholic steatohepatitis and celiac disease.

**■ CELIAC DISEASE
AND MALABSORPTION**

Celiac disease is an immune-mediated disorder that causes mucosal injury to the small intestine, leading to malabsorption. It is triggered by gluten intake in genetically susceptible individuals. The HLA-DQ2 haplotype is expressed in nearly 90% of patients with the disease.

Most cases of self-limited diarrhea resolve in 4 weeks

The worldwide prevalence of celiac disease is about 0.6% to 1%. Those with an affected first-degree relative, type 1 diabetes, Hashimoto thyroiditis, an autoimmune disease, Down syndrome, Turner syndrome, or IgA deficiency have an increased risk.

Celiac disease presents with chronic diarrhea, weight loss, and abdominal distention and pain. Sequelae of nutrient malabsorption such as iron-deficiency anemia, short stature, and osteopenia may be evident. Liver function may also be impaired. Dermatitis herpetiformis and gluten ataxia are rarer presentations of celiac disease.¹²

In the absence of immunoglobulin (Ig) A deficiency, measurement of serum IgA anti-tissue transglutaminase antibodies is recommended for initial testing. IgG antitissue transglutaminase antibodies can be measured in those with IgA deficiency.¹²

Duodenal biopsies to confirm the diagnosis are recommended in adults unless they have previously had biopsy-proven dermatitis herpetiformis.

Gluten-free diet

The treatment for celiac disease is avoidance of gluten. Patients who consult with a nutritionist and participate in an advocacy group are more likely to adhere to a gluten-free diet, and the physician should strongly encourage and facilitate these activities.¹³

Untreated disease can lead to osteoporosis, impaired splenic function with increased risk of infection with encapsulated organisms, infertility or recurrent abortion, ulcerative jejunoileitis, and lymphoma.¹² Patients should be monitored annually for adherence to the gluten-free diet and for the development of any associated condition. Despite adherence to a gluten-free diet, calcium absorption and bone mineral density are lower in patients with celiac disease than in controls.¹⁴ Careful monitoring of fracture risk and adequate calcium and vitamin D replacement are also important.

Our patient undergoes dual-emission x-ray absorptiometry after discharge, with results consistent with osteopenia. His T scores range from -0.2 at the right hip to -1.1 in the left femoral neck.

Recurrence or persistently abnormal levels

TABLE 4

Results of serologic testing

Test	Result	Reference range
Celiac endomysial IgA	Positive	
Celiac gliadin IgA (EU/mL)	102	< 6.1
Celiac gliadin IgG (EU/mL)	51	< 4.9
Celiac tissue transglutaminase IgA (U/mL)	94	< 10.3

of IgA anti-tissue transglutaminase antibodies usually indicates poor dietary compliance.¹²

5 In patients whose symptoms do not improve on gluten restriction, there should be concern for which of the following?

- Lymphoma
- Nonadherence to gluten restriction
- Microscopic colitis
- All of the above

The answer is all of the above. Up to 30% of patients have persistent symptoms on a gluten-free diet. Persistent exposure to gluten is the most common reason for lack of clinical improvement. In addition, bacterial overgrowth of the small bowel, lactose intolerance, pancreatic insufficiency, and microscopic colitis may coexist with celiac disease and may contribute to ongoing symptoms. In a small subset of patients with persistent villous atrophy and symptoms despite strict adherence to a gluten-free diet for 12 months, the disease is deemed “refractory.” Refractory celiac disease can be a precursor to enteropathy-associated T-cell lymphoma.¹³

CASE CONCLUDED

On telephone follow-up 3 weeks after discharge, the patient reports complete resolution of diarrhea and stabilization of his weight. He reports strict adherence to a gluten-free diet and feels he is coping well.

Diagnoses

- Presenting weakness secondary to dehydration and hypokalemia
- Dyspnea secondary to respiratory compensation for metabolic acidosis
- Non-anion-gap metabolic acidosis second-

Greasy stools and marked weight loss make fatty diarrhea more likely

DIARRHEA AND WEAKNESS

- ary to diarrhea
- Acute kidney injury secondary to iodinated contrast, volume depletion, hypotension

- Chronic diarrhea secondary to celiac disease
- Coagulopathy secondary to fat malabsorption secondary to celiac disease. ■

REFERENCES

1. Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. *Gastroenterology* 1999; 116:1464–1486.
2. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ 3rd. Self-reported diarrhea: what does it mean? *Am J Gastroenterol* 1994; 89:1160–1164.
3. Sweetser S. Evaluating the patient with diarrhea: a case-based approach. *Mayo Clin Proc* 2012; 87:596–602.
4. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. *Arch Intern Med* 2001; 161:1989–1996.
5. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. *Drug Saf* 2000; 22:53–72.
6. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. *Mayo Clin Proc* 2012; 87:732–738.
7. Zestril (lisinopril) tablets. www.accessdata.fda.gov/drugsatfda_docs/label/2012/019777s062lbl.pdf. Accessed September 8, 2015.
8. Whittier WL, Rutecki GW. Primer on clinical acid-base problem solving. *Dis Mon* 2004; 50:122–162.
9. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. *Am J Gastroenterol* 2008; 103:162–169.
10. Khouri MR, Ng SN, Huang G, Shiau YF. Fecal triglyceride excretion is not excessive in pancreatic insufficiency. *Gastroenterology* 1989; 96:848–852.
11. Dominici R, Franzini C. Fecal elastase-1 as a test for pancreatic function: a review. *Clin Chem Lab Med* 2002; 40:325–332.
12. Fasano A, Catassi C. Celiac disease. *New Engl J Med* 2012; 367:2419–2426.
13. Mooney PD, Hadjivassiliou M, Sanders DS. Coeliac disease. *BMJ* 2014; 348:g1561–g1561.
14. Pazianas M, Butcher GP, Subhani JM, et al. Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. *Osteoporos Int* 2005; 16:56–63.

ADDRESS: Areeba Y. Kara, MD, MS, FACP, Indiana University School of Medicine, 1633 N. Capitol Avenue, Methodist Medical Tower, Suite 640, Indianapolis, IN 46202; e-mail: akara@iuhealth.org



4th Annual Primary Care Evidence-Based Medicine Update “Evidence that Matters”

October 30 – 31, 2015

Cleveland Clinic Administrative Campus
Building #4, Auditorium
Beachwood, OH

PRESENTING THE 4TH ANNUAL PRIMARY CARE EVIDENCE-BASED MEDICINE UPDATE

Family practitioners, more than any other health care providers, are required to be knowledgeable of the most recent practices in a wide array of medical specialties.

This educational activity is designed to address primary care clinicians' knowledge and educational needs through short presentations that review and analyze recent findings from pertinent clinical research, with a specific focus on research studies that have immediate implications for practice. Most of the studies reviewed will be well-designed randomized clinical trials and meta-analyses.

Register Today! ccfcme.org/2015PrimaryCare

This activity has been approved for AMA PRA Category 1 Credit™.

